<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21054850</article-id><article-id pub-id-type="pmc">3220000</article-id><article-id pub-id-type="publisher-id">cc9320</article-id><article-id pub-id-type="doi">10.1186/cc9320</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Role of selective V<sub>2</sub>-receptor-antagonism in septic shock: a randomized, controlled, experimental study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Rehberg</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Sebastian_Rehberg@web.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Ertmer</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ertmerc@gmx.net</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Lange</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lanm@gmx.de</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Morelli</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>andrea.morelli@uniroma1.it</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Whorton</surname><given-names>Elbert</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>ewhorton@utmb.edu</email></contrib><contrib contrib-type="author" id="A6"><name><surname>D&#x000fc;nser</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Martin.Duenser@i-med.ac.at</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Strohh&#x000e4;cker</surname><given-names>Anne-Katrin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anne-kathrinstrohhaecker@gmx.de</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Lipke</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lipkeerik@aol.com</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Kampmeier</surname><given-names>Tim G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tim.kampmeier@freenet.de</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Van Aken</surname><given-names>Hugo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hva@anit.uni-muenster.de</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Traber</surname><given-names>Daniel L</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>dltraber@utmb.edu</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Westphal</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>martin.westphal@gmx.net</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Anesthesiology and Intensive Care, University of Muenster, Albert-Schweitzer-Str. 33, Muenster 48149, Germany</aff><aff id="I2"><label>2</label>Department of Anesthesiology and Intensive Care, University of Rome, 'La Sapienza', Viale del Policlinico 155, 00161 Rome, Italy</aff><aff id="I3"><label>3</label>Department of Biostatistics and Epidemiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77550, USA</aff><aff id="I4"><label>4</label>Department of Intensive Care Medicine, Inselspital, Medical University of Bern, CH-3010 Bern, Switzerland</aff><aff id="I5"><label>5</label>Investigational Intensive Care Unit, Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77550, USA</aff><pub-date pub-type="ppub"><year>2010</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2010</year></pub-date><volume>14</volume><issue>6</issue><fpage>R200</fpage><lpage>R200</lpage><history><date date-type="received"><day>30</day><month>4</month><year>2010</year></date><date date-type="rev-recd"><day>14</day><month>6</month><year>2010</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2010 Rehberg et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Rehberg et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/14/6/R200"/><abstract><sec><title>Introduction</title><p>V<sub>2</sub>-receptor (V<sub>2</sub>R) stimulation potentially aggravates sepsis-induced vasodilation, fluid accumulation and microvascular thrombosis. Therefore, the present study was performed to determine the effects of a first-line therapy with the selective V<sub>2</sub>R-antagonist (Propionyl<sub>1</sub>-D-Tyr(Et)<sub>2</sub>-Val<sub>4</sub>-Abu<sub>6</sub>-Arg<sub>8,9</sub>)-Vasopressin on cardiopulmonary hemodynamics and organ function vs. the mixed V<sub>1a</sub>R/V<sub>2</sub>R-agonist arginine vasopressin (AVP) or placebo in an established ovine model of septic shock.</p></sec><sec><title>Methods</title><p>After the onset of septic shock, chronically instrumented sheep were randomly assigned to receive first-line treatment with the selective V<sub>2</sub>R-antagonist (1 &#x003bc;g/kg per hour), AVP (0.05 &#x003bc;g/kg per hour), or normal saline (placebo, each <italic>n </italic>= 7). In all groups, open-label norepinephrine was additionally titrated up to 1 &#x003bc;g/kg per minute to maintain mean arterial pressure at 70 &#x000b1; 5 mmHg, if necessary.</p></sec><sec><title>Results</title><p>Compared to AVP- and placebo-treated animals, the selective V<sub>2</sub>R-antagonist stabilized cardiopulmonary hemodynamics (mean arterial and pulmonary artery pressure, cardiac index) as effectively and increased intravascular volume as suggested by higher cardiac filling pressures. Furthermore, left ventricular stroke work index was higher in the V<sub>2</sub>R-antagonist group than in the AVP group. Notably, metabolic (pH, base excess, lactate concentrations), liver (transaminases, bilirubin) and renal (creatinine and blood urea nitrogen plasma levels, urinary output, creatinine clearance) dysfunctions were attenuated by the V<sub>2</sub>R-antagonist when compared with AVP and placebo. The onset of septic shock was associated with an increase in AVP plasma levels as compared to baseline in all groups. Whereas AVP plasma levels remained constant in the placebo group, infusion of AVP increased AVP plasma levels up to 149 &#x000b1; 21 pg/mL. Notably, treatment with the selective V<sub>2</sub>R-antagonist led to a significant decrease of AVP plasma levels as compared to shock time (<italic>P </italic>&#x0003c; 0.001) and to both other groups (<italic>P </italic>&#x0003c; 0.05 vs. placebo; <italic>P </italic>&#x0003c; 0.001 vs. AVP). Immunohistochemical analyses of lung tissue revealed higher hemeoxygenase-1 (vs. placebo) and lower 3-nitrotyrosine concentrations (vs. AVP) in the V<sub>2</sub>R-antagonist group. In addition, the selective V<sub>2</sub>R-antagonist slightly prolonged survival (14 &#x000b1; 1 hour) when compared to AVP (11 &#x000b1; 1 hour, <italic>P </italic>= 0.007) and placebo (11 &#x000b1; 1 hour, <italic>P </italic>= 0.025).</p></sec><sec><title>Conclusions</title><p>Selective V<sub>2</sub>R-antagonism may represent an innovative therapeutic approach to attenuate multiple organ dysfunction in early septic shock.</p></sec></abstract></article-meta><notes><p>See related commentary by Landry and Oliver, <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/14/6/1011">http://ccforum.com/content/14/6/1011</ext-link></p></notes></front><body><sec><title>Introduction</title><p>Arginine vasopressin (AVP) is recommended by the Surviving Sepsis Campaign to 'be subsequently added to norepinephrine' in volume- and catecholamine-refractory septic shock [<xref ref-type="bibr" rid="B1">1</xref>]. In the randomized, controlled, multicenter Vasopressin and Septic Shock Trial (VASST), however, AVP failed to reduce overall mortality as compared with norepinephrine among patients with septic shock [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>AVP represents a mixed V<sub>1a</sub>/V<sub>2 </sub>receptor (V<sub>1a</sub>R/V<sub>2</sub>R) agonist with a selectivity of 1:1 for each of these receptors. Whereas particular attention has been paid to the vasoconstriction mediated by vascular V<sub>1a</sub>Rs [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>], there is increasing evidence that stimulation of extrarenal (endothelial) V<sub>2</sub>Rs [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>] may aggravate sepsis-induced vasodilation [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>], fluid accumulation [<xref ref-type="bibr" rid="B9">9</xref>], leukocyte rolling [<xref ref-type="bibr" rid="B10">10</xref>], and microvascular thrombosis [<xref ref-type="bibr" rid="B11">11</xref>]. Against this background, selective V<sub>2</sub>R-antagonism potentially represents a new therapeutic approach in septic shock.</p><p>We hypothesized that a first-line therapy with the selective V<sub>2</sub>R-antagonist (propionyl<sub>1</sub>-D-Tyr(Et)<sub>2</sub>-Val<sub>4</sub>-Abu<sub>6</sub>-Arg<sub>8,9</sub>) vasopressin [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] is more effective than infusion of placebo and AVP in restoring cardiovascular and renal functions in early ovine septic shock. Open-label norepinephrine was additionally titrated to maintain mean arterial pressure (MAP) in each group if necessary. Therefore, the present study was designed as a prospective, randomized, controlled, laboratory experiment to elucidate the effects of these treatment strategies on cardiopulmonary hemodynamics, mesenteric blood flow, global oxygen transport, acid-base balance, organ function, AVP plasma levels, oxidative stress, and mortality. The study hypothesis was tested in an established ovine model of fulminant septic shock resulting from generalized fecal peritonitis [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>].</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Instrumentation and surgical procedures</title><p>After approval by the Local Animal Research Committee, 21 female sheep were anesthetized, mechanically ventilated, and instrumented for chronic hemodynamic monitoring using an established protocol [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Details on the instrumentation and surgical procedures are provided in the supplemental digital content in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p></sec><sec><title>Experimental protocol</title><p>Following baseline (BL) measurements, autologous feces were injected into the peritoneal cavity via an intraperitoneal suction catheter. When septic shock had developed (so-called 'shock time' [ST], defined as MAP of less than 60 mm Hg), a second set of measurements was performed. The animals were then randomly assigned to receive a first-line therapy with the selective V<sub>2</sub>R-antagonist (1 &#x003bc;g/kg per hour; <italic>n </italic>= 7; Bachem Distribution Services AG, Weil am Rhein, Germany), AVP (0.05 &#x003bc;g/kg per hour, equivalent to 0.5 mU/kg per minute or 0.035 U/minute in a 70-kg patient; <italic>n </italic>= 7; American Regent Inc., Shirley, NY, USA), or normal saline (<italic>n </italic>= 7; B. Braun Melsungen AG, Melsungen, Germany). Open-label norepinephrine (Arterenol; Aventis Pharma, Frankfurt, Germany) was additionally titrated up to 1 &#x003bc;g/kg per minute to maintain MAP at 70 &#x000b1; 5 mm Hg in all groups, if necessary. To ensure normovolemia, continuous infusions of balanced isotonic crystalloids (Sterofundin ISO; B. Braun Melsungen AG, Melsungen, Germany) and 6% hydroxyethyl starch 130/0.4 (Voluven; Fresenius Kabi, Bad Homburg, Germany) were infused at 8 and 4 mL/kg per hour, respectively, after ST. Additional fluids (crystalloid/colloid ratio of 2:1) were infused if hematocrit exceeded BL values during the 24-hour study period [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Hemodynamic measurement, blood gas, laboratory, and histological analyses</title><p>Hemodynamic measurements, arterial and mixed venous blood gas, and laboratory analyses of variables of organ dysfunction and AVP plasma levels were performed at specific time points. Details on these measurements are provided in the supplemental digital content in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p></sec><sec><title>Immunohistochemical analyses</title><p>Following death, tissue samples were immediately stored for immunohistochemical analyses. Pulmonary concentrations of hemeoxygenase-1 (StressXpress Human HO-1 ELISA [enzyme-linked immunosorbent assay] Kit; Stressgen Bioreagents, Ann Arbor, MI, USA) and 3-nitrotyrosine (Hycult biotechnology 3-nitrotyrosine solid-phase ELISA; Cell Sciences, Canton, MA, USA) were determined as described previously [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p></sec><sec><title>Statistical analyses</title><p>Sigma Stat 3.1 software (Systat Software, Inc., San Jose, CA, USA) was used for statistical analyses. Analysis-of-variance methodologies appropriate for two-factor experiments with repeated measures across time for each animal were used. Each variable was analyzed separately for differences among groups and differences across time and for group by time interaction. After confirmation of the significance of different group effects over time, <italic>post hoc </italic>pairwise comparisons among groups were performed using the Student-Newman-Keuls procedure to adjust for the elevated false-positive rate found otherwise in multiple testing. After 10 hours, no statistical analyses were performed, because the small number of animals alive in the placebo and the AVP group did not allow reliable testing anymore. Survival times were calculated using a log-rank test. Group differences were analyzed by pairwise multiple comparison with the Holm-Sidak test. Differences were considered statistically significant for <italic>P </italic>values of less than 0.05.</p></sec></sec><sec><title>Results</title><sec><title>Baseline characteristics</title><p>There were no differences among study groups in any of the investigated variables at BL and ST. Mean body weight (37 &#x000b1; 1 kg) and time to onset of septic shock (7 &#x000b1; 1 hours) did not differ between groups.</p></sec><sec><title>Cardiopulmonary hemodynamics</title><p>Changes in cardiopulmonary variables are presented in Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref> and Table <xref ref-type="table" rid="T1">1</xref>. Septic shock was characterized by decreases in MAP, systemic vascular resistance index, and left ventricular stroke work index (LVSWI) (ST: <italic>P </italic>&#x0003c; 0.001 versus BL each). All three treatment strategies maintained MAP within the target range of 70 &#x000b1; 5 mm Hg for the first 4 hours after ST (4 hours: <italic>P </italic>&#x0003c; 0.01 versus ST each; Table <xref ref-type="table" rid="T1">1</xref>). However, after the dose limitation for norepinephrine had been reached, MAP and systemic vascular resistance index fell significantly below ST values in all groups (10 hours: <italic>P </italic>&#x0003c; 0.05 versus ST each; Table <xref ref-type="table" rid="T1">1</xref>). There were no statistically significant differences in cumulative norepinephrine requirements among study groups (Figure <xref ref-type="fig" rid="F1">1a</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Cumulative norepinephrine requirements (a) and left ventricular function curves (b)</bold>. <italic>n </italic>= 7 each. AVP, arginine vasopressin; LVSWI, left ventricular stroke work index; NE<sub>cum</sub>, cumulative norepinephrine dose; PAOP, pulmonary artery occlusion pressure.</p></caption><graphic xlink:href="cc9320-1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Cardiac filling pressures</bold>. Central venous pressure <bold>(a) </bold>and pulmonary artery occlusion pressure <bold>(b)</bold>. *<italic>P </italic>&#x0003c; 0.05 versus shock time (ST); <sup>&#x02021;</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>&#x000a7;</sup><italic>P </italic>&#x0003c; 0.05 versus arginine vasopressin (AVP); <italic>n </italic>= 7 each. BL, baseline; CVP, central venous pressure; PAOP, pulmonary artery occlusion pressure.</p></caption><graphic xlink:href="cc9320-2"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Cardiopulmonary variables and mesenteric blood flow</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="center">Group</th><th align="center">Baseline</th><th align="center">Shock time</th><th align="center">4 hours</th><th align="center">8 hours</th><th align="center">10 hours</th></tr></thead><tbody><tr><td align="left">HR, beats per min</td><td align="center">Placebo</td><td align="center">96 &#x000b1; 2</td><td align="center">103 &#x000b1; 4</td><td align="center">123 &#x000b1; 7<sup>a</sup></td><td align="center">115 &#x000b1; 7</td><td align="center">102 &#x000b1; 5</td></tr><tr><td/><td align="center">AVP</td><td align="center">93 &#x000b1; 2</td><td align="center">101 &#x000b1; 5</td><td align="center">112 &#x000b1; 6</td><td align="center">99 &#x000b1; 5<sup>b</sup></td><td align="center">100 &#x000b1; 2</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">95 &#x000b1; 4</td><td align="center">102 &#x000b1; 3</td><td align="center">112 &#x000b1; 6<sup>a</sup></td><td align="center">115 &#x000b1; 3<sup>a,c</sup></td><td align="center">101 &#x000b1; 2</td></tr><tr><td align="left">CI, L/min per m<sup>2</sup></td><td align="center">Placebo</td><td align="center">5.5 &#x000b1; 0.3</td><td align="center">5.8 &#x000b1; 0.5</td><td align="center">8.6 &#x000b1; 0.8<sup>a</sup></td><td align="center">7.9 &#x000b1; 0.5<sup>a</sup></td><td align="center">5.8 &#x000b1; 0.6</td></tr><tr><td/><td align="center">AVP</td><td align="center">5.2 &#x000b1; 0.3</td><td align="center">6.5 &#x000b1; 0.4</td><td align="center">8.5 &#x000b1; 0.9</td><td align="center">6.4 &#x000b1; 0.8</td><td align="center">5.4 &#x000b1; 0.8</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">5.3 &#x000b1; 0.2</td><td align="center">5.9 &#x000b1; 0.3</td><td align="center">9.7 &#x000b1; 0.5<sup>a</sup></td><td align="center">8.2 &#x000b1; 0.5<sup>a</sup></td><td align="center">7.1 &#x000b1; 0.4</td></tr><tr><td align="left">SVRI, dyne&#x000b7;s/cm<sup>5 </sup>per m<sup>2</sup></td><td align="center">Placebo</td><td align="center">1,285 &#x000b1; 109</td><td align="center">758 &#x000b1; 52<sup>d</sup></td><td align="center">636 &#x000b1; 60</td><td align="center">463 &#x000b1; 38<sup>a</sup></td><td align="center">457 &#x000b1; 107<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">1,427 &#x000b1; 101</td><td align="center">664 &#x000b1; 47<sup>d</sup></td><td align="center">596 &#x000b1; 109</td><td align="center">498 &#x000b1; 84</td><td align="center">479 &#x000b1; 97<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">1,406 &#x000b1; 25</td><td align="center">714 &#x000b1; 46<sup>d</sup></td><td align="center">509 &#x000b1; 76<sup>a</sup></td><td align="center">388 &#x000b1; 54<sup>a</sup></td><td align="center">464 &#x000b1; 75<sup>a</sup></td></tr><tr><td align="left">MAP, mm Hg</td><td align="center">Placebo</td><td align="center">91 &#x000b1; 4</td><td align="center">58 &#x000b1; 4<sup>d</sup></td><td align="center">66 &#x000b1; 3<sup>a</sup></td><td align="center">55 &#x000b1; 3</td><td align="center">44 &#x000b1; 3<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">93 &#x000b1; 2</td><td align="center">57 &#x000b1; 1<sup>d</sup></td><td align="center">68 &#x000b1; 2<sup>a</sup></td><td align="center">56 &#x000b1; 4</td><td align="center">43 &#x000b1; 1<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">96 &#x000b1; 2</td><td align="center">58 &#x000b1; 1<sup>d</sup></td><td align="center">68 &#x000b1; 3<sup>a</sup></td><td align="center">54 &#x000b1; 2</td><td align="center">51 &#x000b1; 3<sup>a</sup></td></tr><tr><td align="left">SVI, mL/m<sup>2</sup></td><td align="center">Placebo</td><td align="center">59 &#x000b1; 4</td><td align="center">58 &#x000b1; 7</td><td align="center">78 &#x000b1; 3<sup>a</sup></td><td align="center">68 &#x000b1; 3</td><td align="center">55 &#x000b1; 7</td></tr><tr><td/><td align="center">AVP</td><td align="center">56 &#x000b1; 3</td><td align="center">64 &#x000b1; 2</td><td align="center">80 &#x000b1; 7</td><td align="center">63 &#x000b1; 7</td><td align="center">55 &#x000b1; 9</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">53 &#x000b1; 2</td><td align="center">57 &#x000b1; 3</td><td align="center">78 &#x000b1; 7<sup>a</sup></td><td align="center">71 &#x000b1; 5</td><td align="center">70 &#x000b1; 3</td></tr><tr><td align="left">LVSWI, g/m per m<sup>2</sup></td><td align="center">Placebo</td><td align="center">67 &#x000b1; 3</td><td align="center">41 &#x000b1; 4<sup>d</sup></td><td align="center">64 &#x000b1; 6<sup>a</sup></td><td align="center">43 &#x000b1; 4</td><td align="center">22 &#x000b1; 4<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">67 &#x000b1; 3</td><td align="center">42 &#x000b1; 2<sup>d</sup></td><td align="center">60 &#x000b1; 3<sup>a</sup></td><td align="center">26 &#x000b1; 2<sup>b</sup></td><td align="center">21 &#x000b1; 4<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">65 &#x000b1; 3</td><td align="center">37 &#x000b1; 2<sup>d</sup></td><td align="center">65 &#x000b1; 5<sup>a</sup></td><td align="center">36 &#x000b1; 1<sup>c</sup></td><td align="center">29 &#x000b1; 2<sup>c</sup></td></tr><tr><td align="left">MPAP, mm Hg</td><td align="center">Placebo</td><td align="center">14 &#x000b1; 1</td><td align="center">20 &#x000b1; 1<sup>d</sup></td><td align="center">22 &#x000b1; 1</td><td align="center">24 &#x000b1; 2<sup>a</sup></td><td align="center">26 &#x000b1; 2<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">15 &#x000b1; 0</td><td align="center">18 &#x000b1; 1<sup>d</sup></td><td align="center">22 &#x000b1; 1<sup>a</sup></td><td align="center">25 &#x000b1; 1<sup>a</sup></td><td align="center">27 &#x000b1; 2<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">15 &#x000b1; 1</td><td align="center">21 &#x000b1; 1<sup>d</sup></td><td align="center">25 &#x000b1; 2<sup>a</sup></td><td align="center">27 &#x000b1; 1<sup>a</sup></td><td align="center">29 &#x000b1; 1<sup>a</sup></td></tr><tr><td align="left">PVRI, dyne&#x000b7;s/cm<sup>5 </sup>per m<sup>2</sup></td><td align="center">Placebo</td><td align="center">106 &#x000b1; 8</td><td align="center">139 &#x000b1; 22</td><td align="center">119 &#x000b1; 15</td><td align="center">119 &#x000b1; 12</td><td align="center">144 &#x000b1; 30</td></tr><tr><td/><td align="center">AVP</td><td align="center">124 &#x000b1; 9</td><td align="center">143 &#x000b1; 8</td><td align="center">90 &#x000b1; 13<sup>a</sup></td><td align="center">81 &#x000b1; 16<sup>a</sup></td><td align="center">150 &#x000b1; 29</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">129 &#x000b1; 9</td><td align="center">150 &#x000b1; 9</td><td align="center">121 &#x000b1; 26</td><td align="center">103 &#x000b1; 8<sup>a</sup></td><td align="center">123 &#x000b1; 10</td></tr><tr><td align="left">Qma, % of baseline</td><td align="center">Placebo</td><td align="center">100 &#x000b1; 0</td><td align="center">109 &#x000b1; 17</td><td align="center">135 &#x000b1; 27</td><td align="center">94 &#x000b1; 17</td><td align="center">60 &#x000b1; 10<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">100 &#x000b1; 0</td><td align="center">95 &#x000b1; 7</td><td align="center">118 &#x000b1; 21</td><td align="center">86 &#x000b1; 16</td><td align="center">41 &#x000b1; 8<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">100 &#x000b1; 0</td><td align="center">95 &#x000b1; 11</td><td align="center">115 &#x000b1; 11</td><td align="center">75 &#x000b1; 6</td><td align="center">43 &#x000b1; 8<sup>a</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>P </italic>&#x0003c; 0.05 versus shock time; <sup>b</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>c</sup><italic>P </italic>&#x0003c; 0.05 versus arginine vasopressin (AVP); <sup>d</sup><italic>P </italic>&#x0003c; 0.05 versus baseline; each group <italic>n </italic>= 7. CI, cardiac index; HR, heart rate; LVSWI, left ventricular stroke work index; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary vascular resistance index; Qma, mesenteric arterial blood flow; SVI, stroke volume index; SVRI, systemic.</p></table-wrap-foot></table-wrap><p>LVSWI increased significantly in all groups at 2 and 4 hours (<italic>P </italic>&#x0003c; 0.05 versus ST each). Notably, LVSWI was higher in the V<sub>2</sub>R-antagonist group than in the AVP group at 8 and 10 hours (Table <xref ref-type="table" rid="T1">1</xref>). Left ventricular contractility, expressed as a Starling-based relationship between LVSWI and preload (pulmonary artery occlusion pressure), was higher in animals treated with the V<sub>2</sub>R-antagonist than with placebo (Figure <xref ref-type="fig" rid="F1">1b</xref>). Cardiac index increased after ST. Heart rate was lower following AVP infusion than in both other groups (8 hours: <italic>P </italic>= 0.027 versus V<sub>2</sub>R-antagonist; <italic>P </italic>= 0.031 versus placebo; Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Central venous and pulmonary artery occlusion pressures, as surrogate variables of cardiac filling pressures, increased in all groups as compared with ST but were higher in animals treated with the V<sub>2</sub>R-antagonist as compared with both other groups (Figure <xref ref-type="fig" rid="F2">2a,b</xref>). Independently from the individual treatment regimen, mean pulmonary artery pressure increased during the study period (8 and 10 hours: <italic>P </italic>&#x0003c; 0.05 versus ST each; Table <xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>Mesenteric blood flow</title><p>Mesenteric blood flow decreased in all groups (10 hours: <italic>P </italic>&#x0003c; 0.05 versus ST each; Table <xref ref-type="table" rid="T1">1</xref>) without any statistically significant differences among groups.</p></sec><sec><title>Pulmonary gas exchange and global oxygen transport</title><p>Besides a lower PaO<sub>2</sub>/FiO<sub>2 </sub>(arterial partial pressure of oxygen/fraction of inspired oxygen) ratio in the V<sub>2</sub>R-antagonist group compared with the placebo group at 4 hours (<italic>P </italic>= 0.039, Table <xref ref-type="table" rid="T2">2</xref>), there were no statistically significant differences between study groups in variables of pulmonary gas exchange and global oxygen transport (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Hematocrit, electrolytes, acid-base balance, and global oxygen transport</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="center">Group</th><th align="center">Baseline</th><th align="center">Shock time</th><th align="center">4 hours</th><th align="center">8 hours</th><th align="center">10 hours</th></tr></thead><tbody><tr><td align="left">Hct, %</td><td align="center">Placebo</td><td align="center">30 &#x000b1; 2</td><td align="center">28 &#x000b1; 2</td><td align="center">30 &#x000b1; 2</td><td align="center">30 &#x000b1; 2</td><td align="center">27 &#x000b1; 2</td></tr><tr><td/><td align="center">AVP</td><td align="center">27 &#x000b1; 2</td><td align="center">26 &#x000b1; 2</td><td align="center">28 &#x000b1; 2</td><td align="center">27 &#x000b1; 1</td><td align="center">28 &#x000b1; 2</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">26 &#x000b1; 1</td><td align="center">25 &#x000b1; 2</td><td align="center">27 &#x000b1; 2</td><td align="center">26 &#x000b1; 2</td><td align="center">27 &#x000b1; 1</td></tr><tr><td align="left">Na<sup>+</sup>, mmol/L</td><td align="center">Placebo</td><td align="center">141 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td></tr><tr><td/><td align="center">AVP</td><td align="center">140 &#x000b1; 1</td><td align="center">139 &#x000b1; 1</td><td align="center">139 &#x000b1; 1</td><td align="center">139 &#x000b1; 1</td><td align="center">138 &#x000b1; 1</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">140 &#x000b1; 0</td><td align="center">139 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td><td align="center">140 &#x000b1; 1</td></tr><tr><td align="left">K<sup>+</sup>, mmol/L</td><td align="center">Placebo</td><td align="center">4.1 &#x000b1; 0.1</td><td align="center">4.3 &#x000b1; 0.2</td><td align="center">4.4 &#x000b1; 0.3</td><td align="center">5.5 &#x000b1; 0.3<sup>a</sup></td><td align="center">6.1 &#x000b1; 0.3<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">3.8 &#x000b1; 0.2</td><td align="center">4.0 &#x000b1; 0.2</td><td align="center">4.1 &#x000b1; 0.1</td><td align="center">5.2 &#x000b1; 0.3<sup>a</sup></td><td align="center">5.6 &#x000b1; 0.4<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">3.9 &#x000b1; 0.3</td><td align="center">4.2 &#x000b1; 0.3</td><td align="center">4.3 &#x000b1; 0.2</td><td align="center">5.1 &#x000b1; 0.3</td><td align="center">5.5 &#x000b1; 0.4<sup>a</sup></td></tr><tr><td align="left">Cl<sup>-</sup>, mmol/L</td><td align="center">Placebo</td><td align="center">108 &#x000b1; 1</td><td align="center">117 &#x000b1; 2<sup>b</sup></td><td align="center">120 &#x000b1; 1</td><td align="center">124 &#x000b1; 1<sup>a</sup></td><td align="center">125 &#x000b1; 1<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">105 &#x000b1; 1</td><td align="center">113 &#x000b1; 1<sup>b</sup></td><td align="center">118 &#x000b1; 1</td><td align="center">121 &#x000b1; 1<sup>a</sup></td><td align="center">123 &#x000b1; 1<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">108 &#x000b1; 1</td><td align="center">115 &#x000b1; 2<sup>b</sup></td><td align="center">118 &#x000b1; 2</td><td align="center">121 &#x000b1; 2</td><td align="center">122 &#x000b1; 2<sup>a</sup></td></tr><tr><td align="left">pH<sub>a</sub>, -log<sub>10 </sub>[H<sup>+</sup>]</td><td align="center">Placebo</td><td align="center">7.39 &#x000b1; 0.01</td><td align="center">7.30 &#x000b1; 0.02<sup>b</sup></td><td align="center">7.20 &#x000b1; 0.02</td><td align="center">7.09 &#x000b1; 0.04<sup>a</sup></td><td align="center">7.01 &#x000b1; 0.06<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">7.42 &#x000b1; 0.01</td><td align="center">7.31 &#x000b1; 0.02<sup>b</sup></td><td align="center">7.22 &#x000b1; 0.02</td><td align="center">7.05 &#x000b1; 0.05<sup>a</sup></td><td align="center">7.04 &#x000b1; 0.06<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">7.42 &#x000b1; 0.02</td><td align="center">7.33 &#x000b1; 0.02<sup>b</sup></td><td align="center">7.28 &#x000b1; 0.01</td><td align="center">7.22 &#x000b1;0.04<sup>c,d</sup></td><td align="center">7.11 &#x000b1; 0.05<sup>a</sup></td></tr><tr><td align="left">PaO<sub>2</sub>/FiO<sub>2</sub>, mm Hg</td><td align="center">Placebo</td><td align="center">516 &#x000b1; 23</td><td align="center">458 &#x000b1; 26</td><td align="center">435 &#x000b1; 43</td><td align="center">217 &#x000b1; 41<sup>a</sup></td><td align="center">149 &#x000b1; 32<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">488 &#x000b1; 23</td><td align="center">492 &#x000b1; 55</td><td align="center">383 &#x000b1; 27<sup>a</sup></td><td align="center">141 &#x000b1; 25<sup>a</sup></td><td align="center">160 &#x000b1; 19<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">465 &#x000b1; 27</td><td align="center">412 &#x000b1; 26</td><td align="center">313 &#x000b1; 20<sup>a,c</sup></td><td align="center">153 &#x000b1; 30<sup>a</sup></td><td align="center">140 &#x000b1; 26<sup>a</sup></td></tr><tr><td align="left">SvO<sub>2, </sub>%</td><td align="center">Placebo</td><td align="center">78 &#x000b1; 3</td><td align="center">74 &#x000b1; 4</td><td align="center">80 &#x000b1; 3</td><td align="center">74 &#x000b1; 1</td><td align="center">60 &#x000b1; 4<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">78 &#x000b1; 1</td><td align="center">76 &#x000b1; 2</td><td align="center">83 &#x000b1; 4</td><td align="center">70 &#x000b1; 5</td><td align="center">72 &#x000b1; 4</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">79 &#x000b1; 2</td><td align="center">78 &#x000b1; 2</td><td align="center">85 &#x000b1; 2</td><td align="center">78 &#x000b1; 3</td><td align="center">68 &#x000b1; 4</td></tr><tr><td align="left">DO<sub>2</sub>I, mL/min per m<sup>2</sup></td><td align="center">Placebo</td><td align="center">731 &#x000b1; 63</td><td align="center">719 &#x000b1; 83</td><td align="center">1,105 &#x000b1; 115<sup>a</sup></td><td align="center">918 &#x000b1; 39</td><td align="center">575 &#x000b1; 92</td></tr><tr><td/><td align="center">AVP</td><td align="center">641 &#x000b1; 58</td><td align="center">739 &#x000b1; 65</td><td align="center">955 &#x000b1; 128</td><td align="center">749 &#x000b1; 99</td><td align="center">620 &#x000b1; 85</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">598 &#x000b1; 36</td><td align="center">664 &#x000b1; 50</td><td align="center">1,132 &#x000b1; 139<sup>a</sup></td><td align="center">936 &#x000b1; 50</td><td align="center">707 &#x000b1; 64</td></tr><tr><td align="left">VO<sub>2</sub>I, mL/min per m<sup>2</sup></td><td align="center">Placebo</td><td align="center">160 &#x000b1; 12</td><td align="center">179 &#x000b1; 14</td><td align="center">181 &#x000b1; 19</td><td align="center">172 &#x000b1; 22</td><td align="center">155 &#x000b1; 21</td></tr><tr><td/><td align="center">AVP</td><td align="center">163 &#x000b1; 13</td><td align="center">167 &#x000b1; 8</td><td align="center">175 &#x000b1; 8</td><td align="center">144 &#x000b1; 25</td><td align="center">123 &#x000b1; 18<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">128 &#x000b1; 17</td><td align="center">153 &#x000b1; 10</td><td align="center">163 &#x000b1; 17</td><td align="center">142 &#x000b1; 13</td><td align="center">132 &#x000b1; 17</td></tr><tr><td align="left">O<sub>2</sub>-ER, %</td><td align="center">Placebo</td><td align="center">23 &#x000b1; 3</td><td align="center">26 &#x000b1; 3</td><td align="center">18 &#x000b1; 3</td><td align="center">18 &#x000b1; 2<sup>a</sup></td><td align="center">26 &#x000b1; 2</td></tr><tr><td/><td align="center">AVP</td><td align="center">24 &#x000b1; 2</td><td align="center">25 &#x000b1; 1</td><td align="center">21 &#x000b1; 6</td><td align="center">21 &#x000b1; 4</td><td align="center">22 &#x000b1; 4</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">20 &#x000b1; 1</td><td align="center">23 &#x000b1; 1</td><td align="center">13 &#x000b1; 1<sup>a</sup></td><td align="center">16 &#x000b1; 2</td><td align="center">20 &#x000b1; 4</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>P </italic>&#x0003c; 0.05 versus shock time; <sup>b</sup><italic>P </italic>&#x0003c; 0.05 versus baseline; <sup>c</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>d</sup><italic>P </italic>&#x0003c; 0.05 versus arginine vasopressin; each group <italic>n </italic>= 7. AVP, arginine vasopressin; DO<sub>2</sub>I, oxygen delivery index; Hct, hematocrit; O<sub>2</sub>-ER, oxygen extraction rate; PaO<sub>2</sub>/FiO<sub>2</sub>, ratio of arterial partial pressure of oxygen and inspiratory oxygen fraction; pH<sub>a</sub>, arterial potentia hydrogenii; SvO<sub>2</sub>, mixed venous oxygen saturation, VO<sub>2</sub>I, oxygen consumption index.</p></table-wrap-foot></table-wrap></sec><sec><title>Capillary leakage</title><p>In all study groups, septic shock was characterized by a marked decrease in plasma protein concentrations (ST: <italic>P </italic>&#x0003c; 0.001 versus BL each) that progressed over the study period (8 hours: <italic>P </italic>&#x0003c; 0.001 versus ST each; Table <xref ref-type="table" rid="T3">3</xref>). At the same time, there were no statistical differences in hematocrit within or among groups (Table <xref ref-type="table" rid="T2">2</xref>), suggesting adequate fluid resuscitation. Cumulative positive net fluid balance was similar with all three treatment regimes (V<sub>2</sub>R-antagonist: 19 &#x000b1; 1 mL/kg per hour; AVP: 17 &#x000b1; 1 mL/kg per hour; placebo: 18 &#x000b1; 2 mL/kg per hour).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Surrogate parameters of organ (dys)function</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="center">Group</th><th align="center">Baseline</th><th align="center">Shock time</th><th align="center">4 hours</th><th align="center">8 hours</th></tr></thead><tbody><tr><td align="left">AST, U/L</td><td align="center">Placebo</td><td align="center">71 &#x000b1; 7</td><td align="center">76 &#x000b1; 6</td><td align="center">81 &#x000b1; 14</td><td align="center">112 &#x000b1; 18<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">71 &#x000b1; 7</td><td align="center">78 &#x000b1; 7</td><td align="center">80 &#x000b1; 12</td><td align="center">77 &#x000b1; 8</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">72 &#x000b1; 8</td><td align="center">74 &#x000b1; 8</td><td align="center">58 &#x000b1; 9</td><td align="center">63 &#x000b1; 10<sup>b</sup></td></tr><tr><td align="left">ALT, U/L</td><td align="center">Placebo</td><td align="center">7 &#x000b1; 2</td><td align="center">9 &#x000b1; 1</td><td align="center">9 &#x000b1; 2</td><td align="center">13 &#x000b1; 3</td></tr><tr><td/><td align="center">AVP</td><td align="center">8 &#x000b1; 3</td><td align="center">11 &#x000b1; 1</td><td align="center">8 &#x000b1; 2</td><td align="center">11 &#x000b1; 2</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">8 &#x000b1; 2</td><td align="center">10 &#x000b1; 3</td><td align="center">5 &#x000b1; 1</td><td align="center">6 &#x000b1; 1<sup>b</sup></td></tr><tr><td align="left">Bilirubin, mg/dL</td><td align="center">Placebo</td><td align="center">0.24 &#x000b1; 0.02</td><td align="center">0.24 &#x000b1; 0.02</td><td align="center">0.26 &#x000b1; 0.04</td><td align="center">0.25 &#x000b1; 0.02</td></tr><tr><td/><td align="center">AVP</td><td align="center">0.25 &#x000b1; 0.02</td><td align="center">0.23 &#x000b1; 0.02</td><td align="center">0.23 &#x000b1; 0.02</td><td align="center">0.18 &#x000b1; 0.04</td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">0.24 &#x000b1; 0.02</td><td align="center">0.23 &#x000b1; 0.02</td><td align="center">0.23 &#x000b1; 0.03</td><td align="center">0.16 &#x000b1;0.03<sup>b</sup></td></tr><tr><td align="left">Plasma protein, mg/dL</td><td align="center">Placebo</td><td align="center">4.3 &#x000b1; 0.2</td><td align="center">1.9 &#x000b1; 0.2<sup>c</sup></td><td align="center">1.2 &#x000b1; 0.1<sup>a</sup></td><td align="center">0.7 &#x000b1; 0.0<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">4.4 &#x000b1; 0.2</td><td align="center">2.1 &#x000b1; 0.1<sup>c</sup></td><td align="center">1.2 &#x000b1; 0.1<sup>a</sup></td><td align="center">0.9 &#x000b1; 0.2<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">4.2 &#x000b1; 0.3</td><td align="center">1.9 &#x000b1; 0.2<sup>c</sup></td><td align="center">1.2 &#x000b1; 0.1</td><td align="center">0.9 &#x000b1; 0.2<sup>a</sup></td></tr><tr><td align="left">Creatinine, mg/dL</td><td align="center">Placebo</td><td align="center">0.8 &#x000b1; 0.1</td><td align="center">0.7 &#x000b1; 0.1</td><td align="center">1.1 &#x000b1; 0.1</td><td align="center">1.5 &#x000b1; 0.1<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">0.7 &#x000b1; 0.1</td><td align="center">0.7 &#x000b1; 0.1</td><td align="center">0.7 &#x000b1; 0.1</td><td align="center">1.3 &#x000b1; 0.2<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">0.8 &#x000b1; 0.1</td><td align="center">0.8 &#x000b1; 0.1</td><td align="center">0.8 &#x000b1; 0.1</td><td align="center">1.1 &#x000b1; 0.2</td></tr><tr><td align="left">Creatinine clearance, mL/min</td><td align="center">Placebo</td><td align="center">270 &#x000b1; 82</td><td align="center">228 &#x000b1; 36</td><td align="center">37 &#x000b1; 10<sup>a</sup></td><td align="center">16 &#x000b1; 3<sup>a</sup></td></tr><tr><td/><td align="center">AVP</td><td align="center">254 &#x000b1; 29</td><td align="center">197 &#x000b1; 42</td><td align="center">214 &#x000b1; 59<sup>b</sup></td><td align="center">24 &#x000b1; 2<sup>a</sup></td></tr><tr><td/><td align="center">V<sub>2 </sub>antagonist</td><td align="center">235 &#x000b1; 43</td><td align="center">198 &#x000b1; 20</td><td align="center">346 &#x000b1; 52<sup>b</sup></td><td align="center">48 &#x000b1; 15<sup>a</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>P </italic>&#x0003c; 0.05 versus shock time; <sup>b</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>c</sup><italic>P </italic>&#x0003c; 0.05 versus baseline; <italic>n </italic>= 7 each. ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVP, arginine vasopressin.</p></table-wrap-foot></table-wrap></sec><sec><title>Metabolic changes and electrolytes</title><p>Septic shock was associated with decreases in arterial pH and base excess (<italic>P </italic>&#x0003c; 0.05 versus BL each and <italic>P </italic>&#x0003c; 0.001 versus BL each, respectively) and increases in arterial lactate concentrations (<italic>P </italic>&#x0003c; 0.05 versus BL each) in all groups (Figure <xref ref-type="fig" rid="F3">3a,b</xref> and Table <xref ref-type="table" rid="T2">2</xref>). These metabolic changes progressed during the observation period (8 hours: <italic>P </italic>&#x0003c; 0.001 versus ST each). However, the increase in arterial lactate concentration was attenuated (8 and 10 hours: <italic>P </italic>&#x0003c; 0.01 each), arterial base excess was less negative, and pH values were higher in the selective V<sub>2</sub>R-antagonist group as compared with the AVP and placebo groups after 8 hours (<italic>P </italic>&#x0003c; 0.05 each). Plasma concentrations of potassium and chloride increased in all groups during the study period (<italic>P </italic>&#x0003c; 0.05 versus ST each) without significant differences among groups.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Arterial base excess (a) and arterial lactate concentrations (b)</bold>. <sup>&#x02020;</sup><italic>P </italic>&#x0003c; 0.05 versus baseline (BL); *<italic>P </italic>&#x0003c; 0.05 versus shock time (ST); <sup>&#x02021;</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>&#x000a7;</sup><italic>P </italic>&#x0003c; 0.05 versus arginine vasopressin (AVP); <italic>n </italic>= 7 each. BE, base excess.</p></caption><graphic xlink:href="cc9320-3"/></fig></sec><sec><title>Laboratory variables of organ function and arginine vasopressin plasma levels</title><p>Alanine aminotransferase and aspartate aminotransferase activity as well as plasma concentrations of bilirubin were reduced by the selective V<sub>2</sub>R-antagonist as compared with placebo animals (8 hours: <italic>P </italic>&#x0003c; 0.05 each; Table <xref ref-type="table" rid="T3">3</xref>). Renal dysfunction was evidenced by a progressive increase in blood urea nitrogen and plasma creatinine concentrations as well as a decrease in urine output and creatinine clearance in placebo animals (Figure <xref ref-type="fig" rid="F4">4</xref> and Table <xref ref-type="table" rid="T3">3</xref>). Infusion of the selective V<sub>2</sub>R-antagonist was associated with an increased creatinine clearance (4 hours: <italic>P </italic>&#x0003c; 0.001), a higher urine output (2 to 4 hours: <italic>P </italic>&#x0003c; 0.001 each), and lower blood urea nitrogen levels (4 to 8 hours: <italic>P </italic>= 0.031 and <italic>P </italic>= 0.023, respectively) as compared with the placebo group. There were no statistical differences in renal and liver function between the V<sub>2</sub>R-antagonist and the AVP group.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Renal function</bold>. <sup>&#x02021;</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <italic>n </italic>= 7 each. AVP, arginine vasopressin; BL, baseline; BUN, blood urea nitrogen; ST, shock time.</p></caption><graphic xlink:href="cc9320-4"/></fig><p>The onset of septic shock was associated with an increase in AVP plasma levels as compared with BL in all groups (<italic>P </italic>&#x0003c; 0.05 versus BL each; Figure <xref ref-type="fig" rid="F5">5</xref>). Whereas AVP plasma levels remained constant in the placebo group, infusion of AVP increased AVP plasma levels up to 149 &#x000b1; 21 pg/mL. Treatment with the selective V<sub>2</sub>R-antagonist led to a significant decrease of AVP plasma levels as compared with ST (<italic>P </italic>&#x0003c; 0.001) and with both other groups (4 to 8 hours: <italic>P </italic>&#x0003c; 0.05 versus placebo; <italic>P </italic>&#x0003c; 0.001 versus AVP).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Arginine vasopressin (AVP) plasma levels</bold>. <sup>&#x02020;</sup><italic>P </italic>&#x0003c; 0.05 versus baseline (BL); *<italic>P </italic>&#x0003c; 0.05 versus shock time (ST); <sup>&#x02021;</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>&#x000a7;</sup><italic>P </italic>&#x0003c; 0.05 versus AVP; <italic>n </italic>= 7 each. BL, baseline.</p></caption><graphic xlink:href="cc9320-5"/></fig></sec><sec><title>Immunohistochemical analyses</title><p>Immunohistochemical analyses of lung tissue revealed an increase in hemeoxygenase-1 concentration in the selective V<sub>2</sub>R-antagonist group as compared with placebo animals (<italic>P </italic>= 0.047; Figure <xref ref-type="fig" rid="F6">6a</xref>). In addition, pulmonary 3-nitrotyrosine concentrations were lower in animals treated with the selective V<sub>2</sub>R-antagonist as compared with AVP (<italic>P </italic>= 0.017; <italic>P </italic>= 0.056 versus placebo; Figure <xref ref-type="fig" rid="F6">6b</xref>).</p><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>Pulmonary hemoxygenase-1 (a) and 3-nitrotyrosine (b) concentrations</bold>. <sup>&#x02021;</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>&#x000a7;</sup><italic>P </italic>&#x0003c; 0.05 versus arginine vasopressin (AVP); <italic>n </italic>= 7 each. 3-NT, 3-nitrotyrosine; HO-1, hemeoxygenase-1.</p></caption><graphic xlink:href="cc9320-6"/></fig></sec><sec><title>Survival time</title><p>All animals died within 17 hours after the onset of septic shock (Figure <xref ref-type="fig" rid="F7">7</xref>). Sheep treated with the selective V<sub>2</sub>R-antagonist had a longer survival time (14 &#x000b1; 1 hours) than animals that received AVP (11 &#x000b1; 1 hours; <italic>P </italic>= 0.007) or placebo (11 &#x000b1; 1 hours; <italic>P </italic>= 0.025). There were no significant differences in survival time between the AVP and sole norepinephrine groups (<italic>P </italic>= 0.727).</p><fig id="F7" position="float"><label>Figure 7</label><caption><p><bold>Kaplan-Meier survival curve</bold>. <sup>&#x02021;</sup><italic>P </italic>&#x0003c; 0.05 versus placebo; <sup>&#x000a7;</sup><italic>P </italic>&#x0003c; 0.05 versus arginine vasopressin (AVP); <italic>n </italic>= 7 each. ST, shock time.</p></caption><graphic xlink:href="cc9320-7"/></fig></sec></sec><sec><title>Discussion</title><p>The major findings of the present study are that first-line therapy with the selective V<sub>2</sub>R-antagonist (a) stabilized cardiopulmonary hemodynamics as effectively, (b) increased cardiac filling pressures, (c) attenuated metabolic acidosis, (d) limited myocardial and renal dysfunction, (e) reduced AVP plasma levels, (f) attenuated tissue injury secondary to nitrosative stress, and (g) slightly prolonged survival in early volume-resuscitated, hyperdynamic ovine septic shock when compared with placebo and AVP infusion.</p><p>The relative vasopressin deficiency [<xref ref-type="bibr" rid="B18">18</xref>] represents the rationale for the use of AVP in the treatment of septic shock. However, only one third of septic shock patients suffer from low AVP plasma levels [<xref ref-type="bibr" rid="B19">19</xref>]. Typically, endogenous AVP secretion increases in the early phase of septic shock and decreases thereafter. Since V<sub>2</sub>Rs are involved in several characteristic pathways of septic shock [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B20">20</xref>], selective V<sub>2</sub>R-antagonism rather than V<sub>2</sub>R-stimulation (for example, via AVP infusion) may be advantageous under these circumstances.</p><p>In the present study, AVP plasma levels increased with the onset of septic shock in all groups and remained at this level in the placebo group during the whole study period. The absence of a 'relative vasopressin deficiency' may be one reason for the ineffectiveness of AVP in reducing norepinephrine requirements as compared with standard treatment with norepinephrine in the placebo group. Another potential explanation is that the AVP dose of 0.05 &#x003bc;g/kg per hour (equivalent to 0.5 mU/kg per minute or 0.035 U/minute in a 70-kg patient) might have been insufficient for the fulminant injury in our model (100% mortality within 17 hours). The latter assumption is in harmony with the observation made in VASST that AVP reduced mortality in less severe septic shock but not in the more severe septic shock population [<xref ref-type="bibr" rid="B2">2</xref>]. In this context, Torgersen and colleagues [<xref ref-type="bibr" rid="B21">21</xref>] recently reported that, in patients with sepsis-induced vasodilatory shock, a supplementary infusion of 0.067 U/minute AVP was more effective in restoring MAP and reducing norepinephrine requirements than the recommended low dose of 0.033 U/minute.</p><p>Interestingly, infusion of the selective V<sub>2</sub>R-antagonist reduced AVP plasma levels as compared with AVP- and placebo-treated animals. This finding appears to be surprising at first glance. In this context, however, it may be of importance that AVP has a positive feedback on its own release via V<sub>2</sub>R [<xref ref-type="bibr" rid="B22">22</xref>]. Therefore, it is most likely that inhibition of this mechanism has accounted for the low AVP plasma levels noticed in the V<sub>2</sub>R-antagonist group.</p><p>Another interesting result of the present study is that the selective V<sub>2</sub>R-antagonist was as effective as AVP in stabilizing cardiopulmonary hemodynamics without increasing volume and norepinephrine requirements. The reduction in metabolic acidosis by the V<sub>2</sub>R-antagonist - as suggested by higher pH values, less negative base excess, and lower lactate levels as compared with both other groups - probably reduced systemic vasodilation [<xref ref-type="bibr" rid="B23">23</xref>] and contributed to an improved efficacy of norepinephrine by increasing the adrenergic receptor sensitivity [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>].</p><p>In this context, it may also be important that extrarenal V<sub>2</sub>R mediates vasorelaxant effects [<xref ref-type="bibr" rid="B4">4</xref>], thereby decreasing MAP and vascular resistance not only in the experimental setting [<xref ref-type="bibr" rid="B26">26</xref>] but also in humans [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B27">27</xref>].</p><p>In addition, the increased cardiac filling pressures in animals treated with the V<sub>2</sub>R-antagonist may have improved systemic hemodynamics. This assumption is supported by the Starling-based relationship between LVSWI and preload (Figure <xref ref-type="fig" rid="F1">1b</xref>). Since hematocrit remained stable in all groups, the increased preload in the V<sub>2</sub>R-antagonist group has most likely been caused by a mobilization of fluid from venous capacity vessels.</p><p>Whereas both the V<sub>2</sub>R-antagonist and AVP increased urine output and creatinine clearance as compared with placebo animals, the V<sub>2</sub>R-antagonist additionally reduced blood urea nitrogen versus placebo. A protective effect of V<sub>2</sub>R-antagonism on renal function is supported by Rondaij and colleagues [<xref ref-type="bibr" rid="B28">28</xref>], who reported that V<sub>2</sub>R agonism caused histological renal lesions in rats and that these lesions were prevented by V<sub>2</sub>R-antagonism.</p><p>In addition, the reduction of oxidative stress, as suggested by immunohistochemical analyses of lung tissues, probably contributed to the attenuated organ dysfunction in the V<sub>2</sub>R-antagonist group as compared with placebo and AVP. Whereas 3-nitrotyrosine represents a stable <italic>in vivo </italic>biomarker of the highly cytotoxic compound peroxynitrite [<xref ref-type="bibr" rid="B29">29</xref>], hemeoxygenase-1 has been reported to provide cytoprotective effects [<xref ref-type="bibr" rid="B30">30</xref>].</p><p>Attenuation of cardiovascular, metabolic, and renal function as well as nitrosative stress in response to first-line V<sub>2</sub>R-antagonist infusion led to a slight prolongation in survival time as compared with AVP and placebo treatment. Such effects on survival time were not observed with AVP, suggesting that its V<sub>2</sub>R agonism might potentially be disadvantageous.</p><p>This study has some limitations that we want to acknowledge. In the absence of source control and antibiotic therapy, the present model was associated with a high mortality (all animals died within the observation period). As a consequence, effects of the investigated therapeutic approaches could be analyzed only during the acute phase of the injury. In addition, the present study was not designed primarily for detecting differences in mortality. For these reasons, data on survival times in the current study should not be overestimated. In addition, conclusions on the clinical relevance of the present findings are limited by the experimental design and the use of previously healthy animals, whereas the majority of patients typically suffer from comorbidities. Finally, the risk of false-positive results in a study with numerous outcome variables and time points has to be taken into consideration.</p></sec><sec><title>Conclusions</title><p>To our knowledge, this is the first study providing evidence that, under conditions with high endogenous AVP plasma levels, first-line treatment with the selective V<sub>2</sub>R-antagonist supplemented with open-label norepinephrine improves cardiovascular, metabolic, liver, and renal function and slightly prolongs survival when compared with first-line therapy with AVP or placebo in ovine septic shock. On the basis of the present findings, the use of selective V<sub>2</sub>R-antagonists potentially represents a new therapeutic approach in the early stage of septic shock.</p></sec><sec><title>Key messages</title><p>&#x02022; V<sub>2</sub>-receptor stimulation aggravates sepsis-induced vasodilation, fluid accumulation, and microvascular thrombosis.</p><p>&#x02022; Arginine vasopressin (AVP) infusion in septic shock may be less effective when endogenous AVP plasma levels are high.</p><p>&#x02022; In ovine septic shock, selective V<sub>2</sub>-receptor-antagonism supplemented with open-label norepinephrine stabilized cardiovascular hemodynamics as effectively as combined AVP and open-label norepinephrine.</p><p>&#x02022; Selective V<sub>2</sub>-receptor-antagonism attenuated metabolic, liver, and renal dysfunction as compared with AVP and placebo therapy in ovine septic shock.</p><p>&#x02022; Selective V<sub>2</sub>-receptor-antagonism might represent a useful therapeutic option in septic shock under conditions with high endogenous AVP plasma levels.</p></sec><sec><title>Abbreviations</title><p>AVP: arginine vasopressin; BL: baseline; ELISA: enzyme-linked immunosorbent assay; LVSWI: left ventricular stroke work index; MAP: mean arterial pressure; ST: shock time; V<sub>1a</sub>R/V<sub>2</sub>R: V<sub>1a</sub>/V<sub>2 </sub>receptor; VASST: Vasopressin and Septic Shock Trial.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SR designed and performed the experiment, summarized and analyzed the data, and wrote the manuscript. CE designed and performed the experiment, summarized and analyzed the data, and edited the manuscript. MW and AM designed the experiment, analyzed the data, and edited the manuscript. ML, EW, MD, HVA, and DLT analyzed the data and edited the manuscript. A-KS, EL, and TGK performed the experiment and summarized the data. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Supplemental Digital Content</bold>. Additional information on the methods and procedures applied in the present study [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>].</p></caption><media xlink:href="cc9320-S1.DOC" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors thank Mareike Schneider, a medical student from the Department of Anesthesiology and Intensive Care at the University of Muenster (Muenster, Germany), for expert technical assistance during the study. This work was supported only by intramural funding of the University of Muenster.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Carlet</surname><given-names>JM</given-names></name><name><surname>Bion</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>MM</given-names></name><name><surname>Jaeschke</surname><given-names>R</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Gerlach</surname><given-names>H</given-names></name><name><surname>Harvey</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>JJ</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Ranieri</surname><given-names>M</given-names></name><name><surname>Ramsay</surname><given-names>G</given-names></name><name><surname>Sevransky</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Townsend</surname><given-names>S</given-names></name><name><surname>Vender</surname><given-names>JS</given-names></name><name><surname>Zimmerman</surname><given-names>JL</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><article-title>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>296</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000298158.12101.41</pub-id><pub-id pub-id-type="pmid">18158437</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>J</given-names></name><name><surname>Walley</surname><given-names>K</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Granton</surname><given-names>J</given-names></name><name><surname>Storms</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Presneill</surname><given-names>J</given-names></name><name><surname>Ayers</surname><given-names>D</given-names></name><article-title>Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>877</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa067373</pub-id><pub-id pub-id-type="pmid">18305265</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Petersen</surname><given-names>MB</given-names></name><article-title>The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2006</year><volume>99</volume><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2006.pto_299.x</pub-id><pub-id pub-id-type="pmid">16918709</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>LK</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Clapp</surname><given-names>LH</given-names></name><article-title>Vasopressin: mechanisms of action on the vasculature in health and in septic shock</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000251127.45385.CD</pub-id><pub-id pub-id-type="pmid">17133186</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>JE</given-names></name><name><surname>Vischer</surname><given-names>UM</given-names></name><article-title>Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)</article-title><source>J Thromb Haemost</source><year>2003</year><volume>1</volume><fpage>682</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1046/j.1538-7836.2003.00190.x</pub-id><pub-id pub-id-type="pmid">12871401</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Bichet</surname><given-names>DG</given-names></name><name><surname>Razi</surname><given-names>M</given-names></name><name><surname>Lonergan</surname><given-names>M</given-names></name><name><surname>Arthus</surname><given-names>MF</given-names></name><name><surname>Papukna</surname><given-names>V</given-names></name><name><surname>Kortas</surname><given-names>C</given-names></name><name><surname>Barjon</surname><given-names>JN</given-names></name><article-title>Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus</article-title><source>N Engl J Med</source><year>1988</year><volume>318</volume><fpage>881</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1056/NEJM198804073181403</pub-id><pub-id pub-id-type="pmid">2965301</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Liard</surname><given-names>JF</given-names></name><article-title>cAMP and extrarenal vasopressin V2 receptors in dogs</article-title><source>Am J Physiol</source><year>1992</year><volume>263</volume><fpage>H1888</fpage><lpage>1891</lpage><pub-id pub-id-type="pmid">1336316</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>JE</given-names></name><name><surname>Lezzi</surname><given-names>M</given-names></name><name><surname>Vischer</surname><given-names>UM</given-names></name><article-title>Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling</article-title><source>J Thromb Haemost</source><year>2003</year><volume>1</volume><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1046/j.1538-7836.2003.00197.x</pub-id><pub-id pub-id-type="pmid">12871421</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Traber</surname><given-names>DL</given-names></name><article-title>Selective V1a receptor agonists in experimental septic shock [Abstract]</article-title><source>Crit Care</source><year>2007</year><volume>11</volume><fpage>P51</fpage><pub-id pub-id-type="doi">10.1186/cc6030</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Kanwar</surname><given-names>S</given-names></name><name><surname>Woodman</surname><given-names>RC</given-names></name><name><surname>Poon</surname><given-names>MC</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name><name><surname>Lefer</surname><given-names>AM</given-names></name><name><surname>Davenpeck</surname><given-names>KL</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name><article-title>Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules</article-title><source>Blood</source><year>1995</year><volume>86</volume><fpage>2760</fpage><lpage>2766</lpage><pub-id pub-id-type="pmid">7545469</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Laporte</surname><given-names>R</given-names></name><name><surname>Enkhbaatar</surname><given-names>P</given-names></name><name><surname>La</surname><given-names>E</given-names></name><name><surname>Wisniewski</surname><given-names>K</given-names></name><name><surname>Traber</surname><given-names>LD</given-names></name><name><surname>Rivi&#x000e8;re</surname><given-names>P</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><article-title>Arginine vasopressin increases plasma levels of von Willebrand factor in sheep</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>P182</fpage><pub-id pub-id-type="doi">10.1186/cc7346</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Manning</surname><given-names>M</given-names></name><name><surname>Klis</surname><given-names>WA</given-names></name><name><surname>Kruszynski</surname><given-names>M</given-names></name><name><surname>Przybylski</surname><given-names>JP</given-names></name><name><surname>Olma</surname><given-names>A</given-names></name><name><surname>Wo</surname><given-names>NC</given-names></name><name><surname>Pelton</surname><given-names>GH</given-names></name><name><surname>Sawyer</surname><given-names>WH</given-names></name><article-title>Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin</article-title><source>Int J Pept Protein Res</source><year>1988</year><volume>32</volume><fpage>455</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3011.1988.tb01376.x</pub-id><pub-id pub-id-type="pmid">3246475</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Manning</surname><given-names>M</given-names></name><name><surname>Przybylski</surname><given-names>J</given-names></name><name><surname>Grzonka</surname><given-names>Z</given-names></name><name><surname>Nawrocka</surname><given-names>E</given-names></name><name><surname>Lammek</surname><given-names>B</given-names></name><name><surname>Misicka</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>LL</given-names></name><name><surname>Chan</surname><given-names>WY</given-names></name><name><surname>Wo</surname><given-names>NC</given-names></name><name><surname>Sawyer</surname><given-names>WH</given-names></name><article-title>Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids</article-title><source>J Med Chem</source><year>1992</year><volume>35</volume><fpage>3895</fpage><lpage>3904</lpage><pub-id pub-id-type="doi">10.1021/jm00099a018</pub-id><pub-id pub-id-type="pmid">1433200</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Kohler</surname><given-names>G</given-names></name><name><surname>Spiegel</surname><given-names>HU</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Moll</surname><given-names>K</given-names></name><name><surname>Schlack</surname><given-names>K</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><fpage>1286</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1470-z</pub-id><pub-id pub-id-type="pmid">19360396</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Rogiers</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><article-title>Beneficial effects of recombinant human activated protein C in a ewe model of septic shock</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><fpage>2594</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000287590.55294.40</pub-id><pub-id pub-id-type="pmid">17901839</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Enkhbaatar</surname><given-names>P</given-names></name><name><surname>Schmalstieg</surname><given-names>FC</given-names></name><name><surname>Kulp</surname><given-names>GA</given-names></name><name><surname>Traber</surname><given-names>LD</given-names></name><name><surname>Morita</surname><given-names>N</given-names></name><name><surname>Cox</surname><given-names>RA</given-names></name><name><surname>Hawkins</surname><given-names>HK</given-names></name><name><surname>Westphal-Varghese</surname><given-names>BB</given-names></name><name><surname>Rudloff</surname><given-names>HE</given-names></name><name><surname>Maybauer</surname><given-names>DM</given-names></name><name><surname>Maybauer</surname><given-names>MO</given-names></name><name><surname>Burke</surname><given-names>AS</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Saunders</surname><given-names>F</given-names></name><name><surname>Horvath</surname><given-names>EM</given-names></name><name><surname>Szabo</surname><given-names>C</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><article-title>Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>1196</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31816a1a0c</pub-id><pub-id pub-id-type="pmid">18379246</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>RA</given-names></name><name><surname>Traber</surname><given-names>LD</given-names></name><name><surname>Morita</surname><given-names>N</given-names></name><name><surname>Enkhbaatar</surname><given-names>P</given-names></name><name><surname>Schmalstieg</surname><given-names>FC</given-names></name><name><surname>Hawkins</surname><given-names>HK</given-names></name><name><surname>Maybauer</surname><given-names>DM</given-names></name><name><surname>Maybauer</surname><given-names>MO</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Burke</surname><given-names>AS</given-names></name><name><surname>Westphal-Varghese</surname><given-names>BB</given-names></name><name><surname>Rudloff</surname><given-names>HE</given-names></name><name><surname>Salsbury</surname><given-names>JR</given-names></name><name><surname>Jodoin</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><article-title>Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>1428</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000215828.00289.B9</pub-id><pub-id pub-id-type="pmid">16540966</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Levin</surname><given-names>HR</given-names></name><name><surname>Gallant</surname><given-names>EM</given-names></name><name><surname>Ashton</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>D'Alessandro</surname><given-names>D</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name><article-title>Vasopressin deficiency contributes to the vasodilation of septic shock</article-title><source>Circulation</source><year>1997</year><volume>95</volume><fpage>1122</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">9054839</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><article-title>Circulating vasopressin levels in septic shock</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1752</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063046.82359.4A</pub-id><pub-id pub-id-type="pmid">12794416</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><article-title>Selective V2-receptor-antagonism as a new therapeutic approach in ovine septic shock</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><fpage>111</fpage><comment>#422</comment><pub-id pub-id-type="doi">10.1007/s00134-009-1595-0</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Torgersen</surname><given-names>C</given-names></name><name><surname>D&#x000fc;nser</surname><given-names>MW</given-names></name><name><surname>Wenzel</surname><given-names>V</given-names></name><name><surname>Jochberger</surname><given-names>S</given-names></name><name><surname>Mayr</surname><given-names>V</given-names></name><name><surname>Schmittinger</surname><given-names>CA</given-names></name><name><surname>Lorenz</surname><given-names>I</given-names></name><name><surname>Schmid</surname><given-names>S</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Grander</surname><given-names>W</given-names></name><name><surname>Luckner</surname><given-names>G</given-names></name><article-title>Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1630-1</pub-id><pub-id pub-id-type="pmid">19756505</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Landgraf</surname><given-names>R</given-names></name><name><surname>Ramirez</surname><given-names>AD</given-names></name><name><surname>Ramirez</surname><given-names>VD</given-names></name><article-title>The positive feedback action of vasopressin on its own release from rat septal tissue in vitro is receptor-mediated</article-title><source>Brain Res</source><year>1991</year><volume>545</volume><fpage>137</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(91)91279-A</pub-id><pub-id pub-id-type="pmid">1830507</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Pedoto</surname><given-names>A</given-names></name><name><surname>Caruso</surname><given-names>JE</given-names></name><name><surname>Nandi</surname><given-names>J</given-names></name><name><surname>Oler</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>SP</given-names></name><name><surname>Tassiopoulos</surname><given-names>AK</given-names></name><name><surname>McGraw</surname><given-names>DJ</given-names></name><name><surname>Camporesi</surname><given-names>EM</given-names></name><name><surname>Hakim</surname><given-names>TS</given-names></name><article-title>Acidosis stimulates nitric oxide production and lung damage in rats</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">9927349</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Simonis</surname><given-names>G</given-names></name><name><surname>Marquetant</surname><given-names>R</given-names></name><name><surname>Rothele</surname><given-names>J</given-names></name><name><surname>Strasser</surname><given-names>RH</given-names></name><article-title>The cardiac adrenergic system in ischaemia: differential role of acidosis and energy depletion</article-title><source>Cardiovasc Res</source><year>1998</year><volume>38</volume><fpage>646</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(98)00057-1</pub-id><pub-id pub-id-type="pmid">9747432</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>AJ</given-names></name><name><surname>Gisolfi</surname><given-names>CV</given-names></name><article-title>Responses of rat mesenteric arteries to norepinephrine during exposure to heat stress and acidosis</article-title><source>J Appl Physiol</source><year>1995</year><volume>78</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">7713840</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Liard</surname><given-names>JF</given-names></name><article-title>Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs</article-title><source>Am J Physiol</source><year>1990</year><volume>258</volume><fpage>H482</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">2137987</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Tagawa</surname><given-names>T</given-names></name><name><surname>Imaizumi</surname><given-names>T</given-names></name><name><surname>Shiramoto</surname><given-names>M</given-names></name><name><surname>Endo</surname><given-names>T</given-names></name><name><surname>Hironaga</surname><given-names>K</given-names></name><name><surname>Takeshita</surname><given-names>A</given-names></name><article-title>V2 receptor-mediated vasodilation in healthy humans</article-title><source>J Cardiovasc Pharmacol</source><year>1995</year><volume>25</volume><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1097/00005344-199503000-00006</pub-id><pub-id pub-id-type="pmid">7769802</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Rondaij</surname><given-names>MG</given-names></name><name><surname>Bierings</surname><given-names>R</given-names></name><name><surname>Kragt</surname><given-names>A</given-names></name><name><surname>Gijzen</surname><given-names>KA</given-names></name><name><surname>Sellink</surname><given-names>E</given-names></name><name><surname>van Mourik</surname><given-names>JA</given-names></name><name><surname>Fernandez-Borja</surname><given-names>M</given-names></name><name><surname>Voorberg</surname><given-names>J</given-names></name><article-title>Dynein-dynactin complex mediates protein kinase A-dependent clustering of Weibel-Palade bodies in endothelial cells</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000191639.08082.04</pub-id><pub-id pub-id-type="pmid">16239597</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Radi</surname><given-names>R</given-names></name><article-title>Nitric oxide, oxidants, and protein tyrosine nitration</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>4003</fpage><lpage>4008</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307446101</pub-id><pub-id pub-id-type="pmid">15020765</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Chung</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Macias</surname><given-names>AA</given-names></name><name><surname>Baron</surname><given-names>RM</given-names></name><name><surname>Perrella</surname><given-names>MA</given-names></name><article-title>Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1172/JCI32730</pub-id><pub-id pub-id-type="pmid">18060048</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Rogiers</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><article-title>Fluid resuscitation in severe sepsis and septic shock: albumin, hydroxyethyl starch, gelatin or ringer's lactate-does it really make a difference?</article-title><source>Shock</source><year>2007</year><volume>27</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000248583.33270.12</pub-id><pub-id pub-id-type="pmid">17438457</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><article-title>Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1301</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005043421801</pub-id><pub-id pub-id-type="pmid">10793162</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Stubbe</surname><given-names>H</given-names></name><name><surname>Sielenkamper</surname><given-names>AW</given-names></name><name><surname>Ball</surname><given-names>C</given-names></name><name><surname>Van Aken</surname><given-names>H</given-names></name><name><surname>Borgulya</surname><given-names>R</given-names></name><name><surname>Bone</surname><given-names>HG</given-names></name><article-title>Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1502</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063042.15272.84</pub-id><pub-id pub-id-type="pmid">12771625</pub-id></mixed-citation></ref></ref-list></back></article>